116 related articles for article (PubMed ID: 27290782)
1. Coming Soon to a Pharmacy Near You.
Dubois W
Diabetes Self Manag; 2016; 33(3):88-91. PubMed ID: 27290782
[TBL] [Abstract][Full Text] [Related]
2. Diffusion into use of exenatide for glucose control in diabetes mellitus: a retrospective cohort study of a new therapy.
Segal JB; Dy SM; Millman EA; Herbert R; Bass EB; Wu A
Clin Ther; 2007 Aug; 29(8):1784-94. PubMed ID: 17919559
[TBL] [Abstract][Full Text] [Related]
3. Patterns of use and expenses associated with mail-service pharmacy in adults with diabetes.
Wu J; Davis-Ajami ML; Noxon V
J Am Pharm Assoc (2003); 2015; 55(1):41-51. PubMed ID: 25539092
[TBL] [Abstract][Full Text] [Related]
4. The path to approval of new drugs for diabetes.
Rendell M
Expert Opin Drug Saf; 2013 Mar; 12(2):195-207. PubMed ID: 23394462
[TBL] [Abstract][Full Text] [Related]
5. FDA approach to the regulation of drugs for diabetes.
Fleming A
Am Heart J; 1999 Nov; 138(5 Pt 1):S338-45. PubMed ID: 10539795
[No Abstract] [Full Text] [Related]
6. Regulatory issues in the approval of new drugs for diabetes mellitus, dyslipidemia, and the metabolic syndrome.
Isaacsohn JL; Troendle AJ; Orloff DG
Am J Cardiol; 2004 Jun; 93(11A):49C-52C. PubMed ID: 15178516
[No Abstract] [Full Text] [Related]
7. IOM urges FDA to be more aggressive in monitoring safety of approved drugs.
Kuehn BM
JAMA; 2012 Jun; 307(23):2475-6. PubMed ID: 22797430
[No Abstract] [Full Text] [Related]
8. Diabetes field cautiously upbeat despite possible setback for leading SGLT2 inhibitor.
Jones D
Nat Rev Drug Discov; 2011 Aug; 10(9):645-6. PubMed ID: 21878967
[No Abstract] [Full Text] [Related]
9. US FDA approves three new drugs for Type 2 diabetes.
Bond T
Expert Rev Clin Pharmacol; 2013 Mar; 6(2):101. PubMed ID: 23593719
[No Abstract] [Full Text] [Related]
10. FDA upholds findings of UGDP study.
JAMA; 1979 Jan; 241(1):17-8. PubMed ID: 758481
[No Abstract] [Full Text] [Related]
11. New drugs: Liraglutide, dalfampridine, and abobotulinumtoxinA.
Hussar DA; Kaczinski J
J Am Pharm Assoc (2003); 2010; 50(3):436-9. PubMed ID: 20452924
[No Abstract] [Full Text] [Related]
12. Evaluating the safety of diabetes drugs: perspective of a Food and Drug Administration insider.
Misbin RI
Diabetes Care; 2005 Oct; 28(10):2573-6. PubMed ID: 16186303
[No Abstract] [Full Text] [Related]
13. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
DiMasi JA
Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
[TBL] [Abstract][Full Text] [Related]
14. Types of glucose-lowering drugs and their mechanisms of action.
Prescrire Int; 2015 Apr; 24(159):105. PubMed ID: 25941709
[No Abstract] [Full Text] [Related]
15. American Diabetes Association meeting (25-29 June 2010, Orlando, Florida).
Mayor S
Prim Care Diabetes; 2011 Apr; 5(1):63-4. PubMed ID: 20728419
[No Abstract] [Full Text] [Related]
16. Cardiovascular safety and diabetes drug development.
Drucker DJ; Goldfine AB
Lancet; 2011 Mar; 377(9770):977-9. PubMed ID: 21316097
[No Abstract] [Full Text] [Related]
17. Assessing the Safety of Glucose-Lowering Drugs - A New Focus for the FDA.
Chong WH; Yanoff LB; Andraca-Carrera E; Thanh Hai M
N Engl J Med; 2020 Sep; 383(13):1199-1202. PubMed ID: 32966719
[No Abstract] [Full Text] [Related]
18. Drug safety. Planned study of Avandia in doubt after FDA review.
Kean S
Science; 2010 Jul; 329(5990):375. PubMed ID: 20651123
[No Abstract] [Full Text] [Related]
19. The UGDP and the FDA audit.
Am Fam Physician; 1979 Jul; 20(1):67. PubMed ID: 377929
[No Abstract] [Full Text] [Related]
20. Biosimilar insulins are coming: what they are, what you need to know.
Edelman S; Polonsky WH; Parkin CG
Curr Med Res Opin; 2014 Nov; 30(11):2217-22. PubMed ID: 25105307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
